Media OutReach
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
“Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project”
HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Greater Bay Area International Clinical Trial Institute of Hong Kong (“GBAICTI“), the Greater Bay Area International Clinical Trials Center of Shenzhen (“BAY TRIAL“), Immuno Cure BioTech (“Immuno Cure“) in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding (“MOU“) in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area (“GBA“), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone.
This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen.
GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform (“Platform“) by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong.
Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: “The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.”
Dr. LI Yichong, Director of BAY TRIAL, said: “This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area’s pharmaceutical and medical device industry.”
Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy (“ART“) can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host’s immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure’s ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART.
Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People’s Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People’s Hospital, Tianjin Second People’s Hospital, The Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.
Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: “We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure’s therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.”
GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national “Healthy China” strategic goals.
Hashtag: #ImmunoCure #醫克生物 #医克生物
https://www.immunocure.hk/
https://www.linkedin.com/company/immuno-cure/
The issuer is solely responsible for the content of this announcement.
About GBAICTI
The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission is to coordinate public and private medical resources in Hong Kong, providing a one-stop support platform for research institutions. This aims to promote process optimization, talent training, and collaboration within the Greater Bay Area, accelerating the research and development of drugs and medical devices, allowing research outcomes to benefit patients more quickly. By closely collaborating with the Greater Bay Area International Clinical Trials Center, it leverages the unique advantages of “one institute, one center” to jointly coordinate cross-border, multi-center clinical trials that meet international standards.
To learn more about GBAICTI, please visit: https://gbaicti.hk/
About BAY TRIAL
The Greater Bay Area International Clinical Trials Center (BAY TRIAL) is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform. This platform provides top-tier clinical trial technical support, operational management, and registration services for domestic and international pharmaceutical and medical device R&D institutions. Additionally, BAY TRIAL will act as a “testing ground” for clinical trial regulation reforms and a “catalyst” for technological innovation, facilitating the alignment of clinical trial regulations and standards with international benchmarks, promoting the development and application of cutting-edge trial technologies, building a collaborative medical technology innovation network in the GBA, and enhancing the region’s competitiveness in the pharmaceutical and medical device industry.
To learn more about BAY TRIAL, please visit: https://baytrial.smart.org.cn/about/index.html
About Immuno Cure
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms.
To learn more about Immuno Cure, please visit: www.immunocure.hk
Media OutReach
TAT partners with Lalisa ‘LISA’ Manobal, Amazing Thailand Ambassador, to invite Tourists to discover the Multitude of Feelings upon travelling in Thailand, unveiling the New TVC “Feel All The Feelings”
Reinforcing Thailand’s position as a trusted, high-quality destination through emotion-driven storytelling
BANGKOK, THAILAND –
The film sets to entice tourists to experience and discover the multitude of feelings to be gained from travelling in Thailand, including happiness, serenity, excitement, challenge, and warmth, to establish Thailand as a valuable and unforgettable travel destination.
Ms Thapanee Kiatphaibool, Governor of the TAT, revealed, “This year, the TAT remains committed to reinforcing Thailand’s image through the ‘Trusted Thailand’ strategy to warmly welcome tourists, while continuing its push to establish Thailand as a ‘Quality Leisure Destination.’ This is to build confidence among tourists who want to create valuable, unforgettable memories at every step of their journey. Recently, we launched the ‘Feel All The Feelings’ campaign, building widespread communication and awareness across various channels. We are kicking off the year with a new commercial featuring ‘Lalisa LISA Manobal’ as the Amazing Thailand Ambassador, who will showcase Thailand’s tourist attractions and the feelings evoked on each visit. The campaign aims to ‘enhance quality’ while distributing revenue and tourists to new potential areas. TAT cordially invites all Thais to be ‘good hosts’ and share memorable Thai travel experiences.
TVC ‘Feel All The Feelings‘ by TAT portrays unseen attractions and diverse emotions awaiting tourists to discover and experience in Thailand. The story’s inception was inspired by tourists’ desire to seek a range of experiences that fulfil them emotionally and spiritually, helping them ‘Feel Alive’ again. TAT is confident that Thailand can be the answer and add vivid hues to tourists’ lives, as we are a land of diversity, colour, and vitality, ready to offer an exceptional experience for visitors to feel every emotion, from happiness, serenity, excitement, and challenge, to the warmth of smiles and hospitality, the intriguing mystery of new places, and the wonder of unseen locations. We believe that every area and every journey in Thailand will not only create impressive memories but also deliver ‘feelings’ that greatly enrich the travel experience.”
In this ad, Lalisa ‘LISA’ Manobal, in her role as the Amazing Thailand Ambassador, invites everyone to experience the ‘feelings within Thailand’. LISA is often asked, “What does Thailand feel like?” and she reveals the feelings she experiences while resting and recharging in Thailand in the commercial, through every emotion, every feeling, and every rhythm of Thailand’s beauty, which is unlike anywhere else in the world. The production also features renowned stars and actors such as Win – Metawin Opas–iamkajorn, Gulf – Kanawut Traipipattanapong, and Blue – Pongtiwat Tangwancharoen, who join the journey and convey these feelings together.
The TVC showcases beautiful locations nationwide, starting with the captivating beauty of the Lanna Candle Ceremony (Phang Prateep) at Wat Chedi Luang in Chiang Mai province, followed by a spectacular view of the ‘floating pagodas’ in Lampang province. Viewers can marvel at the sea of mist at Phu Langka in Phayao province. The ads also features attractions in other regions to show that, wherever you are, there is always something to discover. Examples include experiencing the beauty of the first light of dawn at Wat Arun in Bangkok, the splendour of the Red Lotus Sea in Udon Thani province, or experiencing the sound of the cascading waters of
Thi Lo Su Waterfall in Tak province.
Furthermore, the “Feel All the Feelings“ campaign aims is to shift tourists from popular landmarks to hidden-gem destinations, increasing the quality of their spending and the value per trip, in line with the “Value over Volume” strategy.
Join “LISA“ on her journey as the Amazing Thailand Ambassador and discover feelings awaiting tourists in Thailand with the “Feel All The Feelings“ campaign. The “Feel All The Feelings“ TVC is currently available at official Amazing Thailand channels:
Youtube: https://youtu.be/wDMv1KujSGc
X (@AmazingThailand) : https://x.com/AmazingThailand/status/2016507144783487483?s=20
Facebook: https://web.facebook.com/share/v/14RnwfmwTTW/
Instagram: https://www.instagram.com/reel/DUDnoOziPCp/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA==
TikTok: https://www.tiktok.com/@amazingthailand/video/7600405546558131476
Contact Information
International Public Relations Division
Tourism Authority of Thailand
Tel: +66 (0) 2250 5500 ext. 4545-48
Fax: +66 (0) 2250 0246
E-mail: [email protected]
Website: www.tatnews.org
Media contacts:
- Khianthong Ngernphum (Thonghom) PR Executive, VERVE Public Relations | E-mail: [email protected] | Tel: +66 80 561 9511
- Jirachaya Jaiyen (Linda) Senior PR Executive, VERVE Public Relations | E-mail: [email protected] | Tel: +66 94 876 4938
Hashtag: #AmazingThailand #AmazingThailandAmbassador #AmazingThailandxLISA #FeelAllTheFeelings #FeelAllTheFeelings_TVC
The issuer is solely responsible for the content of this announcement.
The Group was also ranked third in Thailand under the international “Best Place to Work in Thailand 2025” certification, reinforcing ONYX’s commitment to sustainable people management and a strong corporate culture.
BANGKOK, THAILAND – Media OuReach Newswire – 30 January 2026 – ONYX Hospitality Group has been recognised as the seventh Best Place to Work in the Asia-Pacific region for 2025, awarded by Best Places to Work, an internationally recognised organisation specialising in workplace assessment and employee experience benchmarking. The recognition reflects the Group’s people-centric workplace practices and a culture that places equal emphasis on employee development and service excellence, and is further reinforced by ONYX’s third-place ranking in Thailand under the “Best Place to Work in Thailand 2025” certification, highlighting the Group’s long-standing focus on sustainable people management and a strong, values-driven corporate culture.
With a diverse portfolio spanning hotels, resorts, serviced apartments, and luxury residences under well-established brands including Amari, OZO, Shama, and Oriental Residence, ONYX Hospitality Group continues to strengthen its position across key strategic markets in the region. As the Group approaches its 60th anniversary in 2026, these accolades further highlight ONYX’s long-standing commitment to building a resilient organisation powered by engaged and capable people.
The “Best Places to Work” certification is an internationally recognised programme that benchmarks organisational excellence in human resource practices and employee engagement. Certification is awarded through a comprehensive evaluation covering employee engagement, employee experience, and the effectiveness of HR policies and practices. In this year’s assessment, ONYX Hospitality Group demonstrated strong performance across multiple dimensions, including a supportive work environment, an open and inclusive corporate culture, and a people development strategy closely aligned with the Group’s regional business direction.
One of the key pillars supporting ONYX’s evolution as a trusted workplace is ONYX Academy, the Group’s comprehensive learning and development institute. ONYX Academy delivers structured programmes spanning foundational skills training, advanced role-specific competency development, and clearly defined career pathways for employees at all levels. By prioritising both future-ready capabilities and practical, applicable skills, the Academy equips team members for sustainable personal and professional growth.
The effectiveness of ONYX Academy has also been recognised at an industry level through multiple honours at the EXA: Employee Experience Awards 2025, including awards for the General Manager Development Programme (GM Track), the NextYou Initiative, the HR Leadership Enhancement Programme, and the Group’s ESG initiatives. These accolades further underscore ONYX Hospitality Group’s long-term and focused commitment to meaningful employee development.
Alongside capability building, ONYX Hospitality Group continues to foster a corporate culture rooted in openness and dynamism, encouraging employees to think creatively, experiment, and contribute new ideas. The Group actively supports agility and adaptability by creating space for diverse voices across the organisation. Employee well-being is also prioritised through the ONYX Cares programme, which holistically supports physical and mental health, relationships, and team engagement—contributing to a work environment that nurtures both individual fulfilment and organisational growth.
Saranya Watanasirisuk, Senior Vice President, Corporate Human Resources, commented: “At ONYX Hospitality Group, we believes that our people are the foundation for delivering exceptional experiences and service. Our success in human resource management is driven by strong leadership support at every level, enabling employees to grow across all dimensions. This commitment spans from recruitment and holistic learning systems to cultivating an environment that encourages creativity, experimentation, and the full expression of individual potential. These efforts have positioned ONYX not only as an employer of choice, but also as an organisation trusted by partners and guests alike.”
Receiving the “Best Place to Work” Certification at both national and regional levels marks another significant milestone for ONYX Hospitality Group. The achievement reinforces its commitment not only to being a regional leader in hospitality management, but also to being an organisation that genuinely values its people.
Looking ahead, ONYX remains dedicated to continuously enhancing the workplace environment and delivering meaningful employee experiences that support long-term growth and sustained competitiveness.
For more information about ONYX Hospitality Group, please visit www.onyx-hospitality.com.
Hashtag: #ONYXHospitalityGroup
https://www.linkedin.com/company/onyx-hospitality-group/
https://www.facebook.com/ONYXHospitalityGroup
https://www.instagram.com/onyxhospitalitygroup/
The issuer is solely responsible for the content of this announcement.
About ONYX Hospitality Group:
ONYX Hospitality Group, a reputable force in Southeast Asia’s hospitality industry, operates a collection of comprehensive yet complementary brands – Amari, OZO, Shama and Oriental Residence – catering to the distinctive needs of discerning business and leisure travellers in Southeast Asia where their expertise lies. In addition to its brand portfolio, ONYX Hospitality Group also operates additional hospitality services across spa and food and beverage. With over five decades of management experience, the company extends its innovative solutions throughout the region, upholding internationally recognised standards and ensuring optimal operational manoeuvrability. By fostering enduring relationships with like-minded business partners, ONYX Hospitality Group delivers unparalleled experiences in a dynamic and competitive market, meeting the ever-evolving demands of travellers.
More information: 
www.onyx-hospitality.com
Media OutReach
SCOPE’s Ultra-Luxury Residential Performance Underscores Strong Investor Confidence in Thailand’s Prime Market
Despite global headwinds including escalating trade disputes, rising commodity prices, and shifting monetary policies, Thailand’s prime residential market remains structurally strong. Bangkok, in particular, continues to attract foreign buyers seeking long-term residential assets that combine lifestyle quality with capital stability. Demand in this segment has been driven less by short-term speculation, and more by purchasers prioritizing quality, identity, and long-term livability.
Commenting on the market outlook, Mr. Yongyutt Chaipromprasith, Chief Executive Officer of SCOPE Company Limited, said: “Thailand offers exceptional value when compared with global cities, not only in pricing but also in quality of life, project standards, and long-term livability. Many international investors view Thai ultra-luxury residences as a safe haven asset, supported by competitive rental yields, lower holding costs, and a lifestyle proposition that few markets can replicate.”
Among its flagship developments, SCOPE Langsuan recorded over 90% sales completion within 2025, reflecting strong demand from discerning buyers. The project’s success highlights a clear shift in buyer behavior: ultra-luxury purchasers are increasingly focused on authenticity, design integrity, and long-term residential value rather than speculative gains.
Central to this appeal is SCOPE’s collaboration with internationally acclaimed designer Thomas Juul-Hansen, whose portfolio includes prominent residential development in New York, notably along the iconic “Millionaire’s Row.” By engaging designers of this caliber, SCOPE reinforces its role as a developer of globally competitive, non-replicable residential projects, rather than locally derivative offerings.
This approach further emphasizes the “value for money” proposition of Thailand’s luxury market. Achieving equivalent design pedigree and spatial quality in global financial capitals would require significantly higher development and acquisition costs.
This philosophy guides every stage of development — from spatial planning and material selection to service design and community environments — ensuring that residences are built to support genuine, long-term living.
From curated common spaces designed as well-being hubs, to personalized residential services and collaborations with world-class architects and designers, SCOPE aims to establish new benchmarks for service-driven, timeless luxury in Thailand’s residential market. This evolution reflects a broader industry shift from competing on physical specifications alone to competing on holistic living experiences.
Looking ahead, Thailand’s ultra-luxury real estate market is transitioning from price-based competition toward differentiation driven by design excellence, development standards, service quality, and long-term livability. This shift strengthens the country’s positioning on the global stage and reinforces ultra-luxury residential assets as stable, long-term investments amid ongoing global uncertainty.
Hashtag: #Scope #Scopecollection
https://scopecollection.com/
https://www.facebook.com/scopecollection?locale=th_TH
https://www.instagram.com/scopecollection/
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn